Abstract
1392P - Dose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have